Drug Profile


Alternative Names: N-Desmethylclozapine; ACP-104

Latest Information Update: 18 Jun 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ACADIA Pharmaceuticals
  • Class Antipsychotics; Dibenzazepines; Nootropics; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists; Muscarinic M1 receptor agonists; Serotonin 2A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 16 Jun 2008 Discontinued - Phase-II for Schizophrenia in USA (PO)
  • 16 Jun 2008 Interim efficacy data from a phase IIb trial in Schizophrenia released by ACADIA Pharmaceuticals
  • 15 Dec 2007 ACADIA Pharmaceuticals completes enrolment in its phase IIb trial for Schziophrenia in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top